This protocol addresses the management of renal artery fibromuscular dysplasia (FMD) in patients with hypertension — the most frequent presenting feature of renal FMD.
Renal artery FMD presenting with hypertension. Hypertension is the predominant symptom in this setting and is the primary driver of treatment decisions.
Management involves antihypertensive therapy; specific classes of blood-pressure agents carry particular recommendations for the renovascular context. Full agent selection and sequencing are available in the structured protocol.
DOI: 10.1177/1358863X18821816
Hypertension is, by far, the most frequent presenting symptom among patients with renal FMD, whereas headache (especially migraine), pulsatile tinnitus, transient ischemic attack (TIA) or stroke may be the hallmark of cerebrovascular FMD.
Although all antihypertensive medication can be prescribed in renovascular hypertension, angiotensin-converting enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARB) have been recommended in this setting.
View source ↗